Document is current
Any future updates will be listed below
-
Authors
Tainta, Mikel
Ecay-Torres, Mirian
de Arriba, Maria
Barandiaran, Myriam
Otaegui-Arrazola, Ane
Iriondo, Ane
Garcia-Sebastian, Maite
Estanga, Ainara
Saldias, Jon
Clerigue, Montserrat
Gabilondo, Alazne
Ros, Naia
Mugica, Justo
Barandiaran, Aitziber
Mangialasche, Francesca
Kivipelto, Miia
Arrospide, Arantzazu
Mar, Javier
Martinez-Lage, Pablo
,
Aquizu, I.
Arrondo, M. A.
Baztarrika, E.
Etxeberria, L.
García-Arrea, E.
García-Domínguez, M.
Imaz, E.
Iparragirre, M.
Iridoy, M.
Larrea, A.
López, M. D.
Martin, F.
Olaskoaga, A.
Pacheco, P.
Pérez-Rodiguez, A. M.
Porres, Y.
Ruibal, M.
San Juan, B.
Tilves, M. J.
Zapirain, E.
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 11 September 2023
Accepted: 16 January 2024
First Online: 27 February 2024
Declarations
:
: The GOIZ ZAINDU feasibility trial was approved by the Euskadi Drug Research Ethics Committee (CEIm-E) (ID: PI2017134). All the participants provided written informed consent.
: All participants provided written informed consent, which included explicit consent for publication of the study results and experience.
: MK is Editor-in-Chief of the journal “Alzheimer’s Research and Therapy”.
